IntoCell, Inc. (KOSDAQ:287840)
South Korea flag South Korea · Delayed Price · Currency is KRW
13,160
-1,540 (-10.48%)
At close: Nov 6, 2026

IntoCell Revenue

IntoCell had revenue of 760.30M KRW in the quarter ending June 30, 2026, with 1,829.58% growth. This brings the company's total for the last twelve months to 3.19B, up 156.17% year-over-year. In the year 2025, IntoCell had annual revenue of 2.30B, down -20.86%. That makes IntoCell the 42,023rd largest company in the world by revenue and 2,559th in South Korea.

Revenue (ttm)
3.19B
Revenue Growth
+156.17%
P/S Ratio
61.93
Revenue / Employee
n/a
Employees
n/a
Market Cap
197.69B

Revenue Chart

Revenue by Geography

  • South Korea 2.88B 99.1%
  • United States 13.04M 0.4%
  • China 12.22M 0.4%
Fiscal year ended Dec 31, 2024 See the full IntoCell breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20252.30B-605.91M-20.86%
Dec 31, 20242.91B1.29B79.72%
Dec 31, 20231.62B--
Dec 31, 2022---
Dec 31, 2021140.03M--
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
HansBiomed124.81B
ROKIT Healthcare32.81B
Genome & Company24.46B
NIBEC22.60B
S.Biomedics16.49B
curacle co.,ltd.8.24B
Kangstem Biotech3.03B
Inventage Lab2.47B
Revenue Rankings